Use of Biosimilar Medications in Oncology

Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States

(2021) Kyle Herndon et al.   BIODRUGS

Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments

(2021) Ian F. Tannock et al.   JOURNAL OF CLINICAL ONCOLOGY

Biosimilar usage in practices within the ASCO PracticeNET learning network.

(2020) Brian Bourbeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost savings of biosimilars in oncology: A single institution experience.

(2020) Megan Mullalley et al.   JOURNAL OF CLINICAL ONCOLOGY

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

(2020) Neelima Denduluri et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

(2020) Charles L Bennett et al.   LANCET ONCOLOGY

FDA's Approval of the First  Biosimilar to Bevacizumab

(2018) Sandra J Casak et al.   CLINICAL CANCER RESEARCH

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

(2018) X. Pivot et al.   EUROPEAN JOURNAL OF CANCER

American Society of Clinical Oncology Statement: Biosimilars in Oncology

(2018) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

(2018) Xavier Pivot et al.   JOURNAL OF CLINICAL ONCOLOGY

Rationale, Opportunities, and Reality of Biosimilar Medications

(2018) Gary H. Lyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

(2018) Mark D. Pegram et al.   BRITISH JOURNAL OF CANCER

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

(2017) Hope S. Rugo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

American Society of Clinical Oncology Statement on the Impact of Utilization Management Policies for Cancer Drug Therapies

(2017)   Journal of Oncology Practice

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

(2017) Andrew D. Zelenetz et al.   Journal of the National Comprehensive Cancer Network

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

(2016) Hillel Cohen et al.   ADVANCES IN THERAPY

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

(2016) Ira Jacobs et al.   Patient Preference and Adherence